Naloxone/oxycodone - Mundipharma

Drug Profile

Naloxone/oxycodone - Mundipharma

Alternative Names: OXN PR; Oxycodone hydrochloride/naloxone hydrochloride - Mundipharma; Oxycodone/naloxone extended release - Mundipharma; Oxycodone/naloxone prolonged release - Mundipharma; Targin; Targinact; Targiniq; Targiniq ER

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mundipharma GmbH
  • Developer Mundipharma GmbH; Purdue Pharma
  • Class Antidotes; Morphinans; Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists; Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Constipation; Pain; Restless legs syndrome
  • Phase II Interstitial cystitis

Most Recent Events

  • 30 Mar 2017 Mundipharma completes a phase III trial in Pain (non-cancer) in China (PO) (NCT01918098)
  • 15 Dec 2016 Biomarkers information updated
  • 26 Sep 2016 Interim efficacy and adverse events data from a phase III extension trial in Pain presented at the 16th World Congress on Pain (WCP-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top